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Introduction: To investigate if decreased histone deacetylase 4 (HDAC4) is associated with human osteoarthritis
(OA) cartilage degeneration by releasing HDAC4 inhibition of runt-related transcription factor-2 (Runx2) resulting in
increase of OA cartilage degeneration-related genes.
Methods: The mRNA and protein levels of HDAC4, Runx2, matrix metalloproteinase (MMP)-13, Indian hedgehog (Ihh)
and type X collagen were detected by performing real-time PCR (RT-PCR), western blotting and immunohistochemistry
on specimens from human OA and normal cartilage. To further explore the mechanism of regulation of Runx2
and OA-related genes by HDAC4, changes in these OA-related genes were further quantified by RT-PCR after
overexpression of HDAC4 and knockdown of HDAC4 by siRNA. Runx2 and MMP-13 promoter activities were
measured by dual luciferase assays.
Results: The levels of HDAC4 in the cartilage from OA patients and healthy 40- to 60-year-old donors were decreased
to 31% and 65% compared with specimens from 20- to 40-year-old healthy donors, respectively (P <0.05). Decreased
HDAC4 was associated with increased Runx2 and other OA-related genes in human OA cartilage, specifically: MMP-13,
Ihh and type X collagen. Exogenous HDAC4 decreased the mRNA levels of Runx2, MMP1, MMP3, MMP-13, type X
collagen, Ihh, ADAMTS-4 and -5, and increased the mRNA of type II collagen. In addition, the data also shows that
overexpression of HDAC4 not only decreased the expression of interleukin (IL)-1β, Cox2 and iNos and increased
the expression of aggrecan, but also partially blocked the effect of IL-1β on expression of catabolic events in
human OA chondrocytes. HDAC4 also inhibited Runx2 promoter activity and MMP13 promotor activity in a
dose-dependent manner. In contrast, inhibition of HDAC4 by TSA drug had an opposite effect.
Conclusions: Our study is the first to demonstrate that decreased HDAC4 contributes, at least in part, to the
pathogenesis of OA cartilage degeneration. Thus, HDAC4 may have chondroprotective properties by inhibiting
Runx2 and OA-related genes.* Correspondence: lei_wei@brown.edu; weixiaochun11@126.com
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Osteoarthritis (OA) is the most prevalent joint disease,
and is characterized by destruction and loss of articular
cartilage, leading to chronic pain and dysfunction. Stud-
ies have demonstrated that aging, genetics and mechan-
ical factors are associated with the development of OA.
However, the molecular mechanisms involved in the
pathogenesis and progression of the disease are not
completely understood.
Recent studies have demonstrated that changes ob-
served in the behavior of chondrocytes in OA cartilage re-
semble those undergone by chondrocytes undergoing
differentiation during embryogenesis [1-6]. Hypertrophic
chondrocytes express matrix metalloproteases (MMPs)
and type X collagen, which cause cartilage degradation as
part of the endochondral ossification process of growth
plate development [7-10]. Chondrocytes residing at the
ends of the long bones maintain a stable phenotype and
are resistant to the hypertrophic state [11]. However, dur-
ing OA, chondrocytes lose the stable phenotype and enter
hypertrophic differentiation, as demonstrated by increased
expression of type X collagen, Ihh, and MMP-13. Cartilage
degeneration in OA is therefore similar to cartilage deg-
radation in the growth plate [12,13].
Histone deacetylase 4 (HDAC4) is a member of the
class IIa histone deacetylase family. Recent studies show
that HADC4 plays an important role in skeletal forma-
tion. In the growth plate, HDAC4 prevents chondrocyte
hypertrophy by inhibiting the activity of runt-related
transcription factor-2 (Runx2), a transcription factor es-
sential for chondrocyte hypertrophy during endochon-
dral bone formation. The HDAC4-null mutant mice
display chondrocyte hypertrophy, increased MMP-13,
and premature ossification of developing bones due to
constitutive expression of Runx2 [14,15]. HDAC4 in-
hibits MMP-13 through binding to the Runx2 promoter
region [15]. Thus, HDAC4 is considered as a central
regulator of chondrocyte hypertrophy and skeletogen-
esis during the growth plate development. However, the
role of HDAC4 in OA chondrocytes is unknown. An in-
crease in Runx2 has been reported in OA cartilage and
is associated with increases in MMP-13 and type X col-
lagen [16,17]. Moreover, decreased HDAC4 mRNA has
been reported in cartilage from OA patients when com-
pared with cartilage from healthy donors [18].
Thus, we put forward the hypothesis that decreased
HDAC4 may be associated with human OA cartilage de-
generation by releasing HDAC4 inhibition of Runx2 and
resulting in increased type X collagen, Ihh, and MMP-13.
To test the hypothesis, we first detected and compared
the expression of HDAC4, Runx2, and OA-related genes
between human OA and normal cartilage. Then we per-
formed a similar comparison after manipulating the ex-
pression of HDAC4 in human OA chondrocytes.Methods
Cartilage specimens
Articular cartilage samples were obtained from patients
with OA at the time of knee replacement surgery (N =
33, 21 females, 12 males, average age 66.58 ± 7.12 year
(mean ± standard deviation (SD)), range 56 to 81 years).
Normal samples of articular cartilage were obtained
from patients undergoing amputation because of trauma
(N = 12, 2 females, 10 males, average age 39.25 ± 13.62,
range 21 to 60). The normal samples were divided into
two groups based on age: 1) a 20- to 40-year-old group
(N = 6, 2 females, 4 males, average age 28.33 ± 7.84, range
20 to 37); and 2) a 40- to 60-year-old group (N = 6, 6
males, average age 50.17 ± 7.78, range 41 to 60). Patients
with rheumatoid arthritis and other autoimmune diseases,
as well as chondrodysplasias and posttraumatic OA, were
excluded from this study. Cartilage specimens from pa-
tients with OA were obtained from the more affected
compartment (usually medial tibial plateaus). Normal car-
tilage samples from patients undergoing amputation were
also obtained from medial tibial plateaus. The absence of
cartilage degeneration in the normal cartilage samples was
confirmed using Safranin-O staining. The study was ap-
proved by the Institutional Review Board at the Second
Hospital of Shanxi Medical University, and informed con-
sent was obtained from each tissue donor.
Histology
Articular cartilages were fixed in 10% formalin for three
days. The specimens were decalcified in EDTA solution,
and embedded in a single block of Paraplast X-tra (Thermo
Fisher Scientific, Hampton, NH, USA). Serial 6-μm-thick
sections were cut by a rotary microtome (Leica RM2125,
Leica Microsystems Ltd, Shanghai, China). Safranin-O
staining was performed and cartilage damage was quan-
tified using the modified Mankin grading system [19].
Chondrocyte isolation and primary culture
Chondrocytes were isolated as previously described [20].
Articular cartilage was dissected with a scalpel and
subjected to digestion with 2 mg/ml proteinase (Sigma-
Aldrich, St Louis, MO, USA) in Hank’s balanced salt
solution (HBSS) (Invitrogen, Carlsbad, CA, USA) for
30 min at 37°C with shaking. After digestion and removal
of the supernatant, the cartilage pieces were washed with
Dulbecco’s modified Eagle’s medium/Ham F-12 (DMEM/
F-12) (Gibco BRL, Paisley, UK), and digested with 1 mg/
ml Type IA collagenase (Sigma-Aldrich, St Louis, MO,
USA) for 6 to 8 h at 37°C with shaking. Enzymatic diges-
tion was stopped by adding DMEM/F-12 containing 10%
fetal bovine serum (FBS) (Invitrogen, Carlsbad, CA, USA).
Isolated cells were filtered through a 100-μm mesh to
remove undigested matrix and the cells were washed
three times with DMEM/F-12. Isolated chondrocytes
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DMEM/F-12 plus 10% FBS at 37°C under a humidified
5% CO2 atmosphere until reaching confluence. Chondro-
cyte phenotype were confirmed by immunocytochemistry
using anti-type-I and anti-type-II collagen monoclonal
antibodies (SC-25974, SC-7764, Santa Cruz Biotechnology,
Santa Cruz, CA, USA). These cells are negative for type I
staining and positive for type II collagen.
DNA constructs and transfections
HDAC4-flag and HDAC4-GFP were a generous gift
from Dr A. R. Means [21]; pGL3-Runx2-LUC (0.6 kb of
rat RUNX2 promoter) was provided by Dr. G. S. Stein
[22]. MMP-13 promoter was a gift provided by Im HJ
and Alliston T [23]. The cells were trypsinized and
placed in six-well culture plates (Becton Dickinson
Labware, Franklin Lakes, NJ, USA) at a density of 1 ×
106 cells/plate. The next day, the first passage cells were
transfected with HDAC4 small interfering RNA (siRNA)
(100 nM), scrambled siRNA control (100 nM) (Cell
Signaling Technology, Danvers, MA, USA), or HDAC4-
flag or control vector (2.5 μg) using the GeneMute siRNA
transfection reagent (SignaGen Laboratories, Gaithersburg,
MD, USA). The cells were harvested for real-time PCR or
western blot analysis respectively 48 h or 72 h after trans-
fection. To investigate how decreased HDAC4 in articular
chondrocytes affects expression of catabolic events in these
cells after the treatment with interleukin (IL)-1 beta, the
OA chondrocytes were transfected with HDAC4 or control
constructs for 48 h, then the cells were stimulated with
or without IL-1 beta (5 ng/ul) for 24 h. After IL-1 beta
treatment, these cells were harvested for real-time PCR.
In order to confirm the transfection efficiency, HDAC4-
GFP or siRNA control (fluorescent conjugate) (Cell
Signaling Technology, Danvers, MA, USA) were trans-
fected to OA chondrocytes. Forty-eight hours after trans-
fection, live green fluorescent protein (GFP)-positive cells
were counted under fluorescence microscopy. Each meas-
urement was made in triplicate.
Immunohistochemistry staining
Immunohistochemistry was performed to detect the dis-
tribution of Runx2、Ihh、type X collagen and MMP-13
in the cartilage specimens. Six-μm paraffin sections were
deparaffinized and treated with 3% hydrogen peroxide
(Sigma-Aldrich, St Louis, MO, USA) to block intrinsic
peroxidase in methanol (Sigma-Aldrich, St Louis, MO,
USA) for 30 min. The sections were digested by 5 mg/
ml hyaluronic acid (HA) in phosphate-buffered saline
(PBS) (Sigma-Aldrich, St Louis, MO, USA) for 20 min.
Normal sheep serum (LI-COR Biosciences, Lincoln, NE,
USA) was used to prevent nonspecific binding. The sec-
tions were incubated with primary antibodies against
human Runx2 (CeMines, Inc, Golden, CO, USA), Ihh,MMP-13 (Santa Cruz Technology, Santa Cruz, CA,
USA) and type X collagen (EMD, Gibbstown, NJ, USA)
respectively at 4°C overnight. The negative control sec-
tions were incubated with IgG isotype control (2 mg/ml)
(R&D, Minneapolis, MN, USA) in PBS. The second day,
the sections were treated sequentially and incubated
with biotinylated secondary antibody and streptavidin-
peroxidase conjugate (Zymed-Invitrogen, Carlsbad, CA,
USA), followed by standardized development in 3′3-di-
aminobenzidine (DAB). The sections were counter-
stained with hematoxylin (Zymed-Invitrogen, Carlsbad,
CA, USA). Photography was performed with a Nikon
E800 microscope (Nikon, Melville, NY, USA).
To detect the expression of HDAC4 in cartilage, 6-μm
sections were analyzed by immunofluorescent staining.
The sections were incubated with goat primary antibody
(sc-5245 Santa Cruz Technology, Santa Cruz, CA, USA),
at 4°C overnight. The negative control sections were
incubated with isotype control (sc-1196-P, Santa Cruz
Technology, Santa Cruz, CA, USA) in PBS. After wash-
ing with PBS, affinity-purified tetramethylrhodamine
(TRITC)-conjugated donkey anti-goat secondary anti-
body (1:500) (Jackson ImmunoResearch Laboratories,
West Grove, PA, USA) was applied with Hoechst nu-
clear dye (0.5 mg/ml) (Pierce, Rockford, IL, USA). The
sections were washed and mounted in GEL/MOUNT™
(Biomeda Corporation, Foster City, CA, USA). Photog-
raphy was performed with a Nikon E800 microscope
(Nikon, Melville, NY, USA).
To confirm that the OA chondrocytes used in this
study were not dedifferentiated, we performed immuno-
histochemistry with type II collagen and type I collagen
staining. 1.5 × 105 cells were seeded on the slide, then
fixed in 4% paraformaldehyde for 20 min at 4°C after
culture for 48 h. After fixation, cells were permeabilized
for 10 min in 0.3% Triton X-100 in PBS and incubated in
3% bovine serum albumin for 1 h. The cells were incu-
bated with primary antibodies against type II collagen and
type I collagen overnight at 4°C (SC-25974, SC-7764,
Santa Cruz Technology, Santa Cruz, CA, USA). The cells
were then incubated with a Texas Red-conjugated second-
ary antibody (SC-2783, Santa Cruz Technology, Santa
Cruz, CA, USA) for 30 min at room temperature, followed
by counterstaining with Hoechst 33242 (Pierce, Rockford,
IL, USA). Photography was performed with a Nikon E800
microscope (Nikon, Melville, NY, USA).
Western blotting
Lysis buffer was used to extract total protein from OA
cartilage and normal cartilage specimens or from chon-
drocytes 72 h after transfection with HDAC4 or HDAC4
siRNA. Protein concentrations were determined with the
BCA Protein Assay Kit (Pierce, Rockford, IL, USA). Total
protein (40 ug) underwent electrophoresis in 10% SDS
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esis, proteins were electroblotted onto a PVDF membrane
from the gel by a wet blotting apparatus (Thermo Fisher
Scientific, Hampton, NH, USA). The membranes were
blocked in Tris-buffered saline (TBS) containing 0.1%
Tween-20 and 5% dry milk at 4°C overnight. The next
day, the membranes were incubated for 6 h at room
temperature with primary antibodies against HDAC4,
Runx2, Ihh, MMP-13 and Col x. The primary antibodies
were diluted 1:500 in TBS containing 0.1% Tween-20
(Sigma-Aldrich, St Louis, MO, USA). Immunoglobulin G
(IgG)-conjugated with horseradish peroxidase (HRP) was
diluted 1:2000 in TBS containing 0.1% Tween-20 and used
as the secondary antibody. The immunoreactive proteins
were detected by chemiluminescence using a commercial
enhanced chemiluminescence (ECL) kit. Parallel gels were
prepared for Coomassie Blue staining to confirm equal
loading of total proteins from cartilage samples. The
membranes were stripped and probed again with anti-β-
actin, to estimate the total protein for equal loading. The
densities of bands were quantified using ChemiDoc™ XRS
+ Software (Bio-Rad, Hercules, CA, USA). The following
primary antibodies were used for western blot analysis
from Santa Cruz Biotechnology, Santa Cruz, CA, USA.
Goat anti-HDAC4 (sc-5245), goat anti-Runx2 (sc-12488),
goat anti-collagen 10A1 (sc-323750), goat anti-MMP-13
(sc-31813), goat anti-Ihh (sc-1196), mouse anti-β-actin
(sc-130301), rabbit anti-goat IgG-HRP (sc-2768), mouse
anti-goat IgG-HRP (sc-2354).
Real time RT-PCR
Total RNA was isolated from OA cartilage and normal
cartilage or from chondrocytes transfected with HDAC4
or HDAC4 siRNA 48 h after the transfection, using Tri-
zol reagent (Invitrogen, Carlsbad, CA, USA). The RNA
was reverse-transcribed into first-strand complementary
cDNA using the iScript™ cDNA synthesis kit (Bio-Rad,
Hercules, CA, USA). The quantification of mRNA was
determined using the QuantiTect SYBR Green PCR kit
(Qiagen, Valencia, CA, USA) according to the manufac-
turer’s protocols. Each reaction was performed in tripli-
cate. HADC4 primers were as follows: forward, 5′-GAG
AGA CTC ACC CTT CCC G-3′, and reverse, 5′-CCG
GTCTGC ACC AAC CAA G-3′. Runx2 primers were as
follows: forward, 5′-GGC AGG CAC AGT CTT CCC-3′,
and reverse, 5′- GGC CCA GTT CTG AAG CAC C -3′.
Ihh primers were as follows: forward, 5′-CAT TGA GAC
TTG ACT GGG CAA C-3′, and reverse, 5′-AGA GCA
GGC TGA GTT GGG AGTCGC-3′. Type II collagen
primers were as follows: forward, 5′-TGA GGG CGC
GGT AGA GAC CC-3′, and reverse, 5′-TGC ACA CAG
CTG CCA GCC TC-3′. Type X collagen primers were as
follows: forward, 5′-GCA CGC AGA ATC CAT CTG
AGA ATA-3′, and reverse, 5′-GAC CAG GAG TAC CTTGCT CTC -3′. MMP-1 primers were as follows: forward,
5′-CCA AAT GGG CTT GAA GCT G-3′, and reverse,
5′-GGT ATC CGT GTA GCA CAT TCT GTC–3′.
MMP-3 primers were as follows: 5′-TTT CCA GGG ATT
GAC TCA AAG A-3′, and reverse, 5′-AAG TGC CCA
TAT TGT GCC TTC-3′. MMP-13 primers were as fol-
lows: forward, 5′-TGC TGCATT CTC CTT CAG GA-3′,
and reverse, 5′-ATG CAT CCA GGG GTC CTGGC-3′.
IL-1 beta primers were as follows: forward, 5′-TCG CCA
GTG AAA TGA TGG CTT A-3′, and reverse 5′-GTC
CAT GGC CAC AAC AAC TGA-3′. iNos primers were
as follows: forward, 5′-CCT TAC GAG GCG AAG AAG
GAC AG-3′, and reverse, 5′-CAG TTT GAG AGA GGA
GGC TCC G-3′. Cox2 primers were as follows: forward,
5′-GAG AGATGTATC CTC CCA CAG TCA-3′, and re-
verse, 5′- GAC CAG GCA CCA GAC CAA AG-3′.
ADAMTS-4 primers were as follows: forward, 5′-GAC
ACG CTG GGT ATG GCT GA-3′, and reverse, 5′-ACT
GAT GCA TGG CTT GGA GTT G-3′. ADAMTS-5
primers were as follows: forward, 5′-TAT GAC AAG
TGC GGA GTA TG -3′ and reverse, 5′-TTC AGG GCT
AAA TAG GCA GT-3′. Aggrecan primers were as fol-
lows: forward, 5′- CAT TCA CCA GTG AGG ACC TCG
T-3′ and forward, 5′-TCA CAC TGC TCA TAG CCT
GCT TC-3′. Amplification conditions were as follows:
2 min of preincubation at 50°C, 10 min at 95°C for en-
zyme activation, and 40 cycles at 95°C denaturation for
10 s, 55°C annealing for 30 s, and 72°C extension for 30 s.
18S was used as an internal control gene to normalize the
mRNA levels. The cycle threshold (Ct) values for 18 s
RNA and that of target genes were measured and calcu-
lated by computer software (IQ50, Bio-Rad Laboratories,
Hercules, CA, USA). Relative transcription levels were cal-
culated as x = 2-ΔΔCT, was used for the calculation of fold
amplification [24].
Reporter gene assays
Prehypertrophic chondrocytes were isolated from the
cephalic part of the sternum of a 17-day-old embryonic
chick as previously described [25,26]. Human chondro-
cyte cell line (C28/12) and chicken chondrocytes were
transiently transfected with 0.5 μg of Runx2 or MMP-13
promoter luciferase reporter plasmid using 5 μL/well of
lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) in
12-well plates. Co-transfections with promoters were
performed with empty vector or different concentra-
tions of expression constructs of HDAC4 as indicated.
In some case, the cells transfected with promoters were
treated with different concentrations of HDAC inhibitor
trichostatin A (TSA) as indicated. Cells were harvested
in 1 × reporter lysis buffer 48 h after transfection. Lucif-
erase activity of Runx2 was read in a luminometer using
the dual luciferase reporter assay and normalized to
Renilla activity (Dual-Luciferase Reporter Assay, Promega,
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triplicate.
Statistical analysis
Analysis of variance (ANOVA) was used to compare the
significant differences among the concentrations of
HDAC4 in normal age-matched control and OA cartil-
age specimens. Two-tailed paired t tests were used to
compare statistically significant differences of the pro-
tein (MMP-13, Ihh, type X collagen) in OA and control
cartilage specimens. Student’s t test was used to com-
pare mRNA levels in cartilage or chondrocytes. ANOVA
was used to compare significant differences among the
effects on promoter activity of Runx2 or MMP13 with
different concentrations of HDAC4 constructs or TSA.
ANOVA was used to compare significant differences
among the effects of HDAC4 on catabolic markers inFigure 1 Decrease of HDAC4 protein determined by western blotting
staining was performed to show degeneration changes in the cartilage fro
the lack thereof in normal cartilage from a 60-year-old male patient and 23
(B) Western blotting showed decreased expression of HDAC4 in human ag
confirm equal loading of total proteins from cartilage samples. (C) Semi-qu
was 31% and 65% in the cartilage of OA patients (n = 6) and the 40 to 60 a
to 40 age group (n = 6). *P represents that the difference was statistically siIL-beta-treated chondrocytes. P <0.05 was considered
significant.
Results
Decrease of HDAC4 protein found by western blotting in
human aging and OA cartilage
First, we analyzed expression of HDAC4 in cartilage sam-
ples from the knee joints of OA patients and compared it
to that in normal cartilage samples from 20- to 40-year-
olds and 40- to 60-year-olds. Safranin O staining demon-
strated degeneration in OA cartilage, and the lack thereof
in normal cartilage (Figure 1A). Western blotting analysis
showed that expression of HDAC4 were decreased in the
40- to 60-year-olds and further decreased in the OA speci-
mens, compared with the specimens obtained from the
20- to 40-year-olds (Figure 1B). β-actin and Coomassie
Blue staining confirmed equal loading of total proteinsin human aging and OA cartilage specimens. (A) Safranin O
m a 61-year-old OA patient undergoing total knee arthroplasty, and
-year-old male patient undergoing amputation because of trauma.
ing and OA cartilage. β-actin and Coomassie Blue staining was used to
ality by densitometry showed that the mean concentration of HDAC4
ge group (n = 6), respectively, compared with the cartilage of the 20
gnificant (P <0.05). HDAC4, histone deacetylase 4; OA, osteoarthritis.
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of western blots showed that, compared with cartilage
specimens from the 20- to 40-year-old group, those
from the OA and 40- to 60-year-old group had 31% and
65% of the concentration of HDAC4, respectively. (P <0.05)
(Figure 1C).
Increased expression of RUNX2 was associated with
decreased HDAC4 in OA cartilage
To evaluate the potential relationship between HDAC4
and Runx2 as dysregulated pathways in OA cartilage, we
analyzed expression of HDAC4 and Runx2 in cartilage
from OA patients and age-matched normal cartilageFigure 2 Increased expression of RUNX2 associated with decreased H
changes in the normal controls, whereas there was joint space narrowing a
normal control and OA patients were shown (A-c). Safranin O staining was
and the lack thereof in normal control. (B-a, B-b) Immunofluorescent histo
HDAC4). HDAC4-positive cells (red) were significantly less in OA cartilage th
magnified area shown at the boxed region below. HDAC4-positive cells we
in normal control. (C-a) Immunohistochemistry was performed to show ex
region indicates the magnified area shown at the right side. (C-b) The mRN
were tested by real-time PCR. (*P <0.05) (C-c,C-d) Western blotting showed
normal control. Semi-quality by densitometry showed the mean concentra
cartilage of normal controls (40- to 60-year- olds) (n = 3) (*P <0.05). HDAC4,
transcription factor-2.specimens from the 40- to 60-year-old group (herein
after called ‘normal cartilage’). Immunofluorescent stain-
ing for HDAC4 was significantly lower in OA cartilage
specimens compared with normal cartilage (Figure 2B).
HDAC4-positive cells were 17% of total cells in OA car-
tilage compared with 90% in normal cartilage (P <0.05)
(Figure 2B). Immunohistochemistry staining showed in-
creased Runx2 in OA cartilage compared with normal
cartilage (Figure 2C-a), and real-time PCR and western
blotting yielded similar findings (Figure 2C-b,C-c,C-d).
Runx2 gene expression was increased 4.4-fold in OA
cartilage compared with the normal controls. (P <0.05)
(Figure 2C-b). Quantification of western blots showedDAC4 in OA cartilage. (A-a) X-ray film showed no radiographic
nd cartilage damage in the OA patients. (A-b) The tibial plateaus from
performed to show degeneration in the cartilage from OA patients
chemistry was used to show HDAC4 staining (blue: nucleus; red:
an the normal control. The upper boxed region indicates the
re decreased to 17% of total cells in OA cartilage compared with 90%
pression of Runx2 in OA cartilage and normal control. The boxed
A levels of Runx2 in OA cartilages (n = 3) and normal controls (n = 6)
expression of Runx2 increased in OA samples compared with the
tion of Runx2 in the cartilage of OA patient (n = 3) compared with the
histone deacetylase 4; OA, osteoarthritis; Runx2, runt-related
Cao et al. Arthritis Research & Therapy 2014, 16:491 Page 7 of 13
http://arthritis-research.com/content/16/6/491that the concentration of Runx2 in the cartilages of OA
patients was increased 212% compared with the normal
cartilages (P <0.05) (Figure 2C-d).
Increased MMP-13, Ihh and type X collagen expression in
OA cartilage
Strong staining for MMP-13, Ihh and type X collagen was
observed in OA cartilage compared with normal cartilage
(Figure 3A). Real-time PCR results indicated that the level
of MMP-13, Ihh and type X collagen increased 5.24-,
2.98- and 3.65-fold, respectively, in OA cartilages com-
pared with normal cartilage (P <0.05) (Figure 3B). Simi-
lar findings were made by western blotting. (Figure 3C).
Semi-quantification of western blots showed that the
concentration of MMP-13, Ihh and type X collagen was
increased 278%, 257% and 251% in cartilage from OA
patients compared with those from normal controls, re-
spectively (P <0.05) (Figure 3C,D).Figure 3 Increased MMP-13, Ihh and type X collagen expression in O
MMP-13, Ihh and type X collagen. The boxed regions indicate the magnifie
level of MMP-13, Ihh and type X collagen increased in OA cartilages (n = 3)
blotting showed expression of MMP-13, Ihh and type X collagen increased
densitometry showed the mean concentration of MMP-13, Ihh and type X
cartilage of normal controls (40- to 60-year-olds) (n = 3) (*P <0.05). MMP, mHDAC4 inhibits Runx2 and MMP-13 expression in human
OA chondrocytes
Primary chondrocyte phenotype was confirmed by im-
munocytochemistry, with negative type I staining and
positive type II collagen (Figure 4A). To confirm the
transfection efficiency, HDAC4-GFP or siRNA control
(fluorescent conjugate) were transfected to OA chon-
drocytes. Our data demonstrated that the average trans-
fection efficiency of GFP-HDAC4 or siRNA control was
around 79.1% (72.6% to 87.6%) or 88.2% (85.4% to
91.2%), respectively (Figure S1 in Additional file 1). To
test whether decreased HDAC4 was associated with in-
creased Runx2 in OA cartilages, OA chondrocytes were
transfected with different concentrations of HDAC4
(1 μg or 2.5 μg) or HDAC4 siRNA (100nM) against
HDAC4. Real-time PCR demonstrated that HDAC4 inhib-
ited Runx2 mRNA in a dose-dependent manner. The
mRNA levels of Runx2 in OA chondrocytes transfectedA cartilage. (A) Immunohistochemistry was performed to detect
d area shown at the right side. (B) Real-time PCR indicates that the
compared with normal cartilage (n = 3) (*P <0.05). (C, D) Western
in OA samples compared with normal controls. Semi-quality by
collagen in the cartilage of OA patients (n = 3) compared with the
atrix metalloprotease; OA, osteoarthritis; SD, standard deviation.
Figure 4 HDAC4 inhibits Runx2 and MMP-13 expression in human OA chondrocytes. (A) Human OA chondrocyte phenotype was
confirmed by immunocytochemistry. The cells were positive for type II, but not for type I collagen. (B) Transfection efficiency of HDAC4 in OA
chondrocytes was validated by western blotting. (C) Real-time PCR results indicated that overexpression of HDAC4 downregulated Runx2. The
experiments were performed in triplicate. Data are presented as means ± SD. (D) HDAC4 inhibited Runx2 promoter activity in the human
chondrocyte cell line (C28/12) in a dose-dependent manner. Conversely, inhibition of HDAC by TSA drug enhanced Runx2 promoter activity in a
dose-dependent manner. * = P <0.05 versus control OA culture; # = P <0.05 versus the group of Runx2 promoter transfection. (E) HDAC4 inhibited
MMP-13 promoter activity in the human chondrocyte cell line (C28/12) in a dose-dependent manner. Conversely, inhibition of HDAC by TSA drug
enhanced MMP-13 promoter activity in a dose-dependent manner. All transfections were performed in triplicate. * = P <0.05 versus control OA
culture; # = P <0.05 versus the group of Runx2 promoter transfection. Data are presented as means ± SD. Values represent the mean ± SD from
three independent experiments. HDAC4, histone deacetylase 4; MMP, matrix metalloprotease; OA, osteoarthritis; Runx2, runt-related transcription
factor-2; SD, standard deviation; TSA, trichostatin A.
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29% and 7% respectively, of those in the control vector
(Figure 4C). Increased HDAC4 protein was confirmed by
western blotting (Figure 4B). Conversely, increased mRNA
of Runx2 was observed in the cells transfected with
HDAC4 siRNA. Western blotting showed that HDAC4
siRNA effectively knock down the expression of HDAC4,
whereas Runx2 mRNA increased 3.9-fold (Figure 4B, C).
To further explore the mechanism of the regulation of
Runx2 and MMP-13 by HDAC4, human chondrocyte cell
line (C28/12) and chicken chondrocytes (data not shown)
transfected with Runx2 or MMP-13 reporter constructs
were treated or co-transfected with different concentrationsof TSA (10 ng/ml or 100 ng/ml) or HDAC4 (0.1 μg, 0.2 μg
or 0.4 μg) respectively. Dual luciferase assay was performed
48 h after transfection. Runx2 or MMP-13 promoter activ-
ity was repressed in a dose-dependent manner by HDAC4.
Conversely, inhibition of HDAC by TSA increases Runx2
or MMP-13 promoter activity in a dose-dependent manner
(P <0.05) (Figure 4D, E).
HDAC4 downregulates OA-related gene expressions in
human OA chondrocytes
Our data showed that overexpression of HDAC4 decreased
the mRNA levels of Ihh, type X collagen, MMP1, MMP3,
MMP-13, IL-1 beta, Cox2, iNos, ADAMTS-4 and -5 in
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57.7%, 54.7%, 45.1% and 48.9%, respectively, of those in
controls (Figure 5A). In addition, the mRNA levels of type
II collagen and aggrecan significantly increased 4.7- and
9.0-fold after HDAC4 transfection (Figure 5A) (P <0.05). In
contrast, knockdown HDAC4 by HDAC4 siRNA showed
an opposite effect (Figure 5B) (P <0.05). The transfection
efficiencies of HDAC4 and HDAC4 siRNA were validated
by real-time PCR (Figure 5A, B).
HDAC4 partially blocks the effect of IL-1 beta on expression
of catabolic events in human OA chondrocytes
Real-time PCR showed that IL-1 beta significantly in-
creased the mRNA levels of MMP-1, MMP3, MMP-13,
iNOS, Cox2, ADAMTS-4 and -5 in the OA chondro-
cytes, respectively compared to those untreated controls.
In addition, the mRNA levels of aggrecan, and type IIFigure 5 HDAC4 downregulates OA-related gene expressions in hum
HDAC4-flag or HDAC4 siRNA. All transfections were performed in triplicate.
Runx2, MMP1, MMP3, MMP-13, type X collagen, Ihh, type II collagen, IL-1 b
HDAC4 or control vector transfection. (B)The mRNA of HDAC4, Runx2, MM
Cox2, iNos, ADAMTS-4 and -5 was tested by real-time PCR after HDAC4 siRNA
MMP, matrix metalloprotease; OA, osteoarthritis; Runx2, runt-related transcript
trichostatin A.collagen significantly decreased after stimulation with
IL-1 beta. Overexpression of HDAC4 partly blocked the
upregulation of MMP-1, MMP3, MMP-13, iNOS, Cox2,
ADAMTS-4, and -5 induced by IL-1 beta. In the mean-
while, the mRNA levels of aggrecan, and type II collagen
significantly increased in those cells transfected by
HDAC4 (Figure 6) (P <0.05).
Discussion
Studies have demonstrated that the class II HDACs are
involved in cellular development and differentiation, and
expressed in a tissue-specific pattern. HDAC4 is expressed
in brain, muscle and cartilage [27,28]. In the growth plate,
HDAC4 is a negative regulator of chondrocyte hypertrophy
by binding to and inhibiting Runx2 - a critical transcrip-
tional factor for chondrocyte hypertrophy [14,26]. How-
ever, the role of HDAC4 during OA cartilage degenerationan OA chondrocytes. Human OA chondrocytes were transfected with
Data are presented as means ± SD. *P <0.05. (A) The mRNA of HDAC4,
eta, Cox2, iNos, ADAMTS-4 and -5 was tested by real-time PCR after
P1, MMP3, MMP-13, type X collagen, Ihh, type II collagen, IL-1 beta,
or scrambled siRNA control transfection. HDAC4, histone deacetylase 4;
ion factor-2; SD, standard deviation; siRNA, small interfering RNA; TSA,
Figure 6 HDAC4 partially blocks the effect of IL-1 beta on expression of catabolic events in human OA chondrocytes. Human OA
chondrocytes were transfected with HDAC4 or control constructs for 48 h, then the cells were stimulated with or without IL-1 beta (5 ng/ ul) for
24 h. All transfections were performed in triplicate. * = P <0.05 versus the group of HDAC4 + IL-1 beta, # = P <0.05 versus the group of control
vercor, ^ = P <0.05 versus the group of control vector + IL-1 beta. Real-time PCR showed that IL-1 beta significantly increased the mRNA levels of
MMP-1, MMP3, MMP-13, iNOS, Cox2, ADAMTS-4 and -5 in the OA chondrocytes, respectively compared to those untreated controls. In addition,
the mRNA levels of aggrecan, and type II collagen significantly decreased after stimulation with IL-1 beta (P <0.05). Overexpression of HDAC4
partly blocked the upregulation of MMP-1, MMP3, MMP-13, iNOS, Cox2, ADAMTS-4, and -5 induced by IL-1 beta. In the meanwhile, the mRNA
levels of aggrecan, and type II collagen significantly increased in those cells transfected by HDAC4 (P <0.05) (n = 3). HDAC4, histone deacetylase
4; IL, interleukin; MMP, matrix metalloprotease; OA, osteoarthritis; Runx2, runt-related transcription factor-2.
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expression of HDAC4 protein decreases with aging in hu-
man cartilage, and furthermore in human OA cartilage
(Figure 1).
In addition to decreased HDAC4, we found that ex-
pression of Runx2, Ihh, MMP-13 and type X collagen is
increased in OA cartilage with respect to normal con-
trols (Figures 2 and 3). This result is also consistent with
previous reports [20,29-32]. Runx2 is a critical regulator
for chondrocyte hypertrophy and contributes to the pro-
gression of OA. Previous studies have reported that Runx2
is activated in OA cartilage and responsible for the in-
crease of MMP-13 and type X collagen in a mouse OA
model and in human OA chondrocytes [8,10,17,33]. Type
X collagen and MMP-13 are markers for chondrocytehypertrophy, and MMP-13 is a primary player in OA car-
tilage damage [32,34-36]. In an in vivo study, the heterozy-
gous Runx2-deficient mice showed decreased cartilage
damage and reduced type X collagen and MMP-13 ex-
pression compared with wild-type mice [10]. These find-
ings suggest that increased Runx2 in OA cartilage may
trigger the expression of a series of genes related to OA
cartilage damage. However, it is unknown how Runx2 is
regulated in OA cartilage. Taken together with the dys-
regulation of the genes in OA cartilage shown in our
study (Figures 2 and 3), it is likely that decreased
HDAC4 is at least partially responsible for the increase
of Runx2 and OA-related genes in OA cartilage. We
hypothesize that decreased HDAC4 in OA cartilage will
release the HDAC4 inhibition of Runx2, thus resulting
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Runx2 activates a series of OA-related genes and results
in cartilage degeneration.
To test whether decreased HDAC4 makes a contribu-
tion to increased Runx2 and other OA-related genes in
human OA cartilage, OA chondrocytes were transfected
with either HDAC4 expression construct or siRNA
against HDAC4. Our data showed that either the mRNA
level of Runx2 were repressed after overexpression of
HDAC4, and the opposite effect was observed when
HDAC4 was knocked down by siRNA (Figures 4 and 5).
Moreover, we also demonstrated that HDAC4 inhibited
Runx2 and MMP-13 promoter activities in a dose-
dependent manner (Figure 4D, E). In contrast, inhib-
ition of HDAC4 by TSA increased Runx2 and MMP-13
promoter activities. HDAC4 and Runx2 are known as
important regulators of chondrocyte hypertrophy during
growth plate development. It is reported that HDAC4 re-
pressed chondrocyte hypertrophy by binding to and inhi-
biting Runx2 transcriptional activity in the chondrocytes
of an embryonic chick [26]. HDAC4-null mice display
ectopic and premature mineralization of endochondral
bones, mimicking the Runx2 gain of function mice [14].
Consistent with this finding, Runx2, Ihh and MMP-13
are greatly increased in HDAC4−/− mice [14,15]. It is
also reported that HDAC4 inhibited MMP-13 through
Runx2 and HDAC4 and 5 were required for transform-
ing growth factor-β-mediated repression on Runx2
function to inhibit osteoblast differentiation [15,37]. A
mechanism of HDAC4 repression on Runx2 has been
proposed in which HDAC4 interacts with Runx2 pro-
tein to deacetylate Runx2 [38]. Our results indicate the
mechanism of HDAC4 acting on Runx2 and MMP-13
in OA chondrocytes is similar to that found in the
growth plate and osteoblasts.
In this study, the reduction of endogenous HDAC4 con-
tributes to the increase of Runx2, type X collagen, and
MMP-13 in OA chondrocytes. We found that the overex-
pression of HDAC4 decreased the mRNA level of MMP1,
MMP3, MMP-13, type X collagen, Ihh ADAMTS-4 and
-5, and increased the mRNA of type II collagen. HDAC4
inhibits chondrocyte hypertrophy by binding to and inhi-
biting Runx2 and MMP-13 [14,26]. Runx2 is a well-
known transcriptional factor that induces MMP-13, Ihh
and ADAMTS-5 production [14,15,39]. Increased Ihh was
associated with chondrocyte hypertrophy and upregula-
tion of MMP1, MMP3, and MMP-13 in a mouse OA
model and human OA cartilage [20,40]. Thus, a mechan-
ism of HDAC4 repression on Runx2 is involved in this
phenomenon. Our data also shows that overexpression of
HDAC4 not only decreased the expression of IL-1 beta,
Cox2 and iNos and increased the expression of aggrecan,
but also partially blocked the effect of IL-1 beta on expres-
sion of catabolic events in human OA chondrocytes. IL-1beta plays a critical role in the cartilage degeneration
[41-43]. However, the mechanism by which HDAC4 regu-
lates IL-1 beta is unclear. Future studies are necessary to
investigate the mechanism of HDAC4 action on IL-1 beta.
These results suggest that upregulation of HDAC4 may
have a chondroprotective effect in patients with early-
stage disease.
Conclusions
In summary, our novel findings indicate, for the first
time, that decreased HDAC4 is at least partially respon-
sible for the increase of Runx2 and OA-related genes in
human OA cartilage. This finding will facilitate our un-
derstanding of the pathogenesis of degenerative cartilage.
Thus, upregulation of HDAC4 may have a chondropro-
tective effect in OA therapy.
Additional file
Additional file 1: Figure S1. The transfection efficiency of GFP-HDAC4
or siRNA control. (A) Efficiency of GFP-HDAC4 transfection was 79.1%
(72.6% to 87.6%). (B) Efficiency of siRNA control transfection was 88.2%
(85.4% to 91.2%). The percentage of cells that are GFP-positive was
detected using fluorescence microscopy. Approximately 300 cells from
three independent experiments were scored.
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